

### **REMARKS**

Applicant respectfully submits that the requirements of 37 C.F.R. §§ 1.821 - 1.825 are believed to have been previously met with the May 7, 2001 Resubmission Pursuant to 37 C.F.R. §§ 1.821 - 1.825, in which the sequence listing from U.S. Serial No. 09/054,492, from which this application claims priority, was requested to be entered into this application. However, for the convenience of the Patent Office, the specification is further corrected and a substitute Sequence Listing is herein submitted to comply with the requirements of an application containing a nucleotide and/or amino acid sequence 37 C.F.R. §§ 1.821 - 1.825. The sequences disclosed in the substitute Sequence Listing are the same sequences as previously submitted in U.S. Serial No. 09/054,492.

The paper copy and computer readable copy (CD-R) of the substitute Sequence Listing are the same. The substitute Sequence Listing does not include new matter.

### **CONCLUSION**

Entry of the substitute Sequence Listing and corrections to the specification, and favorable consideration are respectfully requested.

Applicants respectfully submit that the application is now believed to be complete. Reconsideration of the Petition and Request to Withdraw Holding of Abandonment filed on July 5, 2004 is respectfully requested.

**To the extent necessary, please grant any extension of time deemed necessary for entry of this communication. Please charge any deficient fees, or credit any overpayment of fees, to Deposit Account 500417.**

Respectfully submitted,  
MCDERMOTT, WILL & EMERY LLP

Date: 9/1/2004

By: Kelli N. Watson  
Kelli N. Watson  
Registration No. 47,170

600 Thirteenth Street, N.W.  
Washington, D.C. 20005-3096  
(202) 756-8351 (Direct)  
(202) 756-8087 (Facsimile)  
WDC99 970657-1.050212.0278